Indeed, efficient pharmacological inhibition of Eg5 determined a substantial reduction of AGS gastric adenocarcinoma cells and a negative modulation of the angiogenic event, presumably through the involvement of PI3K-Akt-VEGF and Erk-VEGF pathways [37]. The gene discussed is VEGFA; the disease is gastric adenocarcinoma.